SCHEMBL6867274

SCHEMBL6867274

CCOC(=O)c1c(OCc2ccccc2)c2ccc(OC3CCCCO3)c(C)c2oc1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 5/20 0.40
MAPT P10636 5/20 0.40
HPGD P15428 3/20 0.40
HSD17B10 Q99714 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
F2 P00734 1/20 0.39
POLB P06746 2/20 0.38
P2RY12 Q9H244 1/20 0.38
TP53 P04637 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
FHIT P49789 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6860106 0.92 SLC26A3 (0.37) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL7793419 0.92 KDM4E (0.42) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL6860056 0.84 HSP90AB1 (0.39) KDM4E
SCHEMBL6860054 0.84 HSP90AB1 (0.39) KDM4E
SCHEMBL6864371 0.83 NPC1 (0.45) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL7193790 0.83 HSP90AB1 (0.36) KDM4E
SCHEMBL6867279 0.81 PDE4B (0.37) RAB9AKDM4EALDH1A1MAPTHPGD
SCHEMBL6866676 0.78 SHBG (0.51) NPC1RAB9AKDM4EALDH1A1MAPT
SCHEMBL6940108 0.77 HSP90AB1 (0.36) KDM4E
SCHEMBL6940113 0.77 HSP90AB1 (0.36) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6812331-B2 BACTERICIDES AVENTIS PHARMA S.A. (FR) 2004-11-02 US disclosed
US-6350733-B1 4-HYDROXYBENZOPYRAN-2-ONE DERIVATIVES; BACTERICIDES FOR STAPHYLOCOCCUS INFECTIONS; SKIN DISORDERS AVENTIS PHARMA S.A. (FR) 2002-02-26 US disclosed
US-20020010322-A1 New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments AVENTIS PHARMA S.A. 2002-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010322-A1 New aromatic derivatives substituted by a ribose, their preparation process and their use as medicaments RPIA, CD38, PARP1 NPC1 1691/4885RAB9A 2505/4885KDM4E 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.